Cancer drug developer Scancell (LON:SCLP) said it has completed patient dosing in part 1 of its on-going Phase 1/2 clinical trial for the SCIB1 ImmunoBody drug.
Five patients with metastatic tumours were given SCIB1, with doses of 8mg. There were no reported serious adverse events.
Scancell said that immunology and clinical responses are currently being analysed, and will be reported to the market by the end of the second quarter.
Previously patients given lower dosage, 4mg, showed an immune response that might be associated with clinical benefit in patients with malignant melanoma.
Scancell also has permission to expand the second part of the study to include up to 13 patients, receiving 8mg. And with the absence of any serious toxicity in part 1, new patients are being recruited for this stage of the study.
The first patient of the part 2 cohort was dosed with SCIB1 earlier this week.
"Our higher dose 8mg SCIB1 study is progressing well,” said joint chief executive Richard Goodfellow.
“In view of the continued safety profile of SCIB1 at the higher dose, we are now recruiting for Part 2 of this cohort, which will assess the immune and clinical response to SCIB1 in a larger number of patients with Stage III/IV melanoma.
“We look forward to reporting the results from Part 1 of the study later this year."